[1]艾力曼·马合木提,Nicolas Meneveau,Francois Schiele,等.经皮冠状动脉介入术中止血活性的早期改变及与纤溶酶原激活剂抑制物鄄1基因多态性的相关性[J].介入放射学杂志,2007,(09):584.
 Ailiman Mahemuti,Nicolas Meneveau,et al.Relationship between plasminogen activator inhibitor-1gene polymorphism and early local hemostatic activation in patients with percutaneous coronary intervention procedure[J].journal interventional radiology,2007,(09):584.
点击复制

经皮冠状动脉介入术中止血活性的早期改变及与纤溶酶原激活剂抑制物鄄1基因多态性的相关性()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2007年09期
页码:
584
栏目:
心脏介入
出版日期:
2007-09-15

文章信息/Info

Title:
Relationship between plasminogen activator inhibitor-1gene polymorphism and early local hemostatic activation in patients with percutaneous coronary intervention procedure
作者:
艾力曼·马合木提Nicolas MeneveauFrancois Schiele
法国Besancon Franche-comté大学Jean-Minjoz大学中心医院心血管中心,25030,Besancon Franch(艾力曼·马合木提、Nicolas Meneveau、Francois Schiele、Jean-Pierre Bassand);新疆医科大学第一附属医院心血管中心(艾力曼·马合木提)
Author(s):
Ailiman Mahemuti 1Nicolas Meneveau 1 Francois Schiele 1 Jean-Pierre Bassand 1 1.
Department of Cardiology and UPRES EA3920-IFR133,University of Franche-ComtéMedical School,University Hospital Jean-Minjoz Hospital,25030Besan con,France.2.Department of Cardiology,the First Affiliated Hospital of Xinjiang Medical University,830054Urumqi,
关键词:
经皮冠状动脉介入术基因多态性纤溶酶原激活剂抑制-1凝血因子Ⅶ可溶性P选择素D-二聚体
分类号:
R541.4
文献标志码:
A
摘要:
目的探讨经皮冠状动脉介入(PCI)术中冠状动脉内血浆纤溶酶原激活剂抑制物-1(PAI-1)、D-二聚体(D-D)、凝血因子Ⅶ(FⅦa)及可溶性P选择素(CD62P)活性在球囊扩张和支架植入前后的早期改变及其与PAI-1基因多态性的相关性,评估其对急性支架血栓形成的预测价值。方法选择稳定型心绞痛患者20例,按标准方法行冠状动脉造影且证实冠状动脉狭窄均在70%以上。术中冠状动脉内血样采集顺序依次为:球囊扩张前冠状动脉入口处(Ostium)用引导导管,球囊扩张15min以后及支架植入后15min通过血栓吸引器穿过病灶在病变远端采血。结果PAI-1基因多态性在本组中分布为4G/5G型最多(12例,60%),4G/4G型其次(6例,30%),5G/5G型最少(2例,10%)。4G和5G等位基因频率分别为60%和40%。具有PAI-14G/5G基因型患者冠状动脉内血浆PAI-1、D-D以及FⅦ活性在球囊扩张后较球囊扩张前明显升高且有统计学意义(P均为0.01),然而这些指标在球囊扩张前与支架植入后比较无显著性差异。结论球囊扩张较支架植入更易损伤血管内皮并导致冠状动脉内局部、早期止血活性的一过性增高,具有PAI-14G/5G基因型患者对这种反应较为敏感。PCI术前双联抗血小板药物可以有效抑制血小板活性。

参考文献/References:

[1]Folson AR,AleKsic N,Park E,et al.Prospective study of fibri-nolytic factors and incident coronary heart disease:the Atherosclerosis Risk in Communities(ARIC)Study[J].Arterioscler Thromb Vasc Biol,2001,21:611-617.
[2]Junker R,Heinrich J,Schulte H,et al.Coagulation factorⅦand the risk of coronary heart disease in healthy men[J].Arterioscler Thromb Vasc Biol,1997,17:1539-1544.
[3]Malik I,Danesh J,Whincup P,et al.Soluble adhesion molecu-les and prediction of coronary heart disease:a prospective study and meta-analysis[J].Lancet,2001,(9286):971-976.
[4]Semenov AV,Koqan-ponomarev M,Ruda M,et al.Soluble P-selectin-a marker of platelet activation and vessel wall injury:increase of soluble P-selectin in plasma of patients with myocardial infarction,massive atherosclerosis and primary pulmonary hypertension(Abstract)[J].Ter Arkh,2000,72:15-20.
[5]Johan-vague I,Morange PE,Frere C,et al.The plasminogen activator inhibitor-1-6754G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe:the HIFMECH study[J].J Thromb Haemost,2003,1:2322-2329.
[6]章顺荣,徐力辛,高秋琦.中国汉族人PAI-1基因多态性与冠心病相关性的Meta分析[J].循证医学,2005,5:282-285.
[7]Guan L,Ji X,Wang J,et al.Association of plasminogen activa-tor inhibitor-1gene4G/5G polymorphism and coronary heart disease in Chinese patients[J].Zhonghua Yi Xue Yi Chuan Xue Za Zhi,2002,19:393-396.
[8]Pastinen T,Perola M,Niini P,et al.Array-based multiplex an-alysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population[J].Hum Mol Genet,1998,7:1453-1462.
[9]Falk G,Almqvist A,Nordenhem A,et al.Allele specific PCR for detection of a sequence polymorphism in the promoter region of the plasminogen activator inhibitor-1(PAI-1)gene[J].Fibrinolysis,1995,9:170-174.
[10]Eriksson P,Kallin B,Van't Hooft FM,et al.Allele-specific increase in basal transcription of the plasminogen-activator inhibitor1gene is associated with myocardial infarction[J].Proc Natl Acad Sci USA,1995,92:1851-1855.
[11]ten Boeked E,de Kieviet W,Bartels PC.Subjects with a short-ened activated partial thromboplastin time show increased in-hospital mortality associated with elevated D-dimer,C-reactive protein and glucose levels[J].Scand J Clin Lab Invest,2003,63:441-448.
[12]Robinson SD,Handing SA,Cummins P,et al.Functional inter-play between platelet activation and endothelial dysfunction in patients with coronary heart disease[J].Platelets,2006,17:158-162.

相似文献/References:

[1]倪靖炜,沈卫峰,张瑞岩,等.冠心病合并慢性肾功能不全患者的临床特征和PCI远期预后分析[J].介入放射学杂志,2007,(03):152.
 NI Jing-wei,SHEN Wei-feng,ZHANG Rui-yan,et al.Clinical characteristics and long-term outcome of PCI in patients with chronic renal insufficiency[J].journal interventional radiology,2007,(09):152.

备注/Memo

备注/Memo:
收稿日期:2007-04-25
更新日期/Last Update: 2007-09-15